静脉自控镇痛在癌痛伴抑郁共病联合用药中的应用研究

摘要:

目的：探讨静脉自控镇痛在癌痛伴抑郁共病联合用药中的应用效果。方法：选取2021年5月至2023年5月本院收集的癌痛伴抑郁共病病人36例，随机分为观察组和对照组，各18例，对照组采用常规口服盐酸吗啡缓释片+吗氯贝胺镇痛抗抑郁治疗，观察组采用静脉自控镇痛盐酸吗啡注射液+口服吗氯贝胺片镇痛抗抑郁治疗，比较两组病人在不同治疗方案干预后癌痛、抑郁程度及癌性爆发痛发作次数。结果：观察组病人疼痛、抑郁程度及癌性爆发痛发作次数明显低于对照组（P＜0.05）。结论：应用静脉自控镇痛联合用药治疗癌痛伴抑郁共病能明显降低病人疼痛、抑郁程度及癌性爆发痛发作次数，具有一定的临床应用价值。

Abstract:

Objective: To explore the application effect of patient-controlled intravenous analgesia in the combination therapy of cancer pain and depression comorbidity. Methods: 36 cases of cancer pain with depression comorbidity patients collected in our hospital from May 2021 to May 2023 were randomly assigned to the observation group and the control group, 18 cases in each group. The control group was treated with conventional oral morphine hydrochloride sustained-release tablets+Moclobemide analgesia and antidepressant treatment, and the observation group was treated with intravenous self-control analgesia morphine hydrochloride injection+oral Moclobemide tablets analgesia and antidepressant treatment The degree of depression and the frequency of cancerous pain outbreaks. Result: The degree of pain, depression, and the frequency of cancerous burst pain attacks in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: The use of intravenous patient-controlled analgesia combined with medication to treat comorbidities of cancer pain and depression can significantly reduce the degree of pain, depression, and the frequency of cancerous burst pain attacks in patients, which has clinical application value.